Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma
About this trial
This is an interventional treatment trial for Childhood Burkitt Lymphoma
Eligibility Criteria
Inclusion Criteria: Newly diagnosed mature B-lineage (CD20-positive) leukemia or lymphoma by the REAL classification of 1 of the following subtypes: Diffuse large cell lymphoma Burkitt's lymphoma High-grade B-cell lymphoma (Burkitt-like) No B-cell anaplastic large cell Ki-1 positive lymphomas and B-lymphoblastic lymphomas One of the following FAB prognostic groups: Group B (intermediate risk) Group C (high risk) Bone marrow involvement with at least 25% blasts and/or CNS involvement meeting 1 or more of the following criteria: Any L3 blasts in cerebrospinal fluid Cranial nerve palsy (if not explained by extracranial tumor) Clinical spinal cord compression Isolated intracerebral mass Parameningeal extension (cranial and/or spinal) Hepatitis B status known Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 6 months after study participation No known history of congenital immune deficiency and/or laboratory evidence of acquired immune deficiency No known G6PD deficiency (if receiving rasburicase) No prior malignancies treated with systemic chemotherapy with alkylator or anthracycline therapy No prior chemotherapy At least 1 week since prior steroids except emergency steroids initiated within 72 hours of study entry No prior radiotherapy except emergency radiotherapy initiated within 72 hours of study entry No concurrent radiotherapy No prior solid organ transplantation
Sites / Locations
- Children's Oncology Group
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Group B (chemotherapy, protective therapy, monoclonal antib.)
Group C (Chemotherapy, monoclonal antibody therapy)
Therapies given IV, IT, orally, or SC. Please see treatment outline. See Detailed Description.
Therapies given IV, IT, orally, or subcutaneously (same as FAB B with the addition of etoposide and high-dose methotrexate). See Detailed Description.